Newswise — Toronto, ON (March 17, 2015) – A comprehensive study examining clinical trials of more than 95,000 patients has found that glucose or sugar-lowering medications prescribed to patients with diabetes may pose an increased risk for the development of heart failure in these patients.
\”Patients randomized to new or more intensive blood sugar-lowering drugs or strategies to manage diabetes showed an overall 14 per cent increased risk for heart failure,\” says Dr. Jacob Udell, the study’s principal investigator, and cardiologist at the Peter Munk Cardiac Centre, University Health Network (UHN) and Women’s College Hospital (WCH). \”This increased risk was directly associated with the type of diabetes therapy that was chosen, with some drugs more likely to cause heart failure than others, compared with placebo or standard care,\” he says.
The results of the study were presented today at the American College of Cardiology’s 64th Annual Scientific Session and published in the current issue of The Lancet Diabetes and Endocrinology.
\”While some drugs showed an increased risk, other strategies tested, such as intensive weight loss to control blood sugar, showed a trend towards a lower risk for heart failure,\” says Dr. Michael Farkouh, senior author of the study and Chair, Peter Munk Centre of Excellence in Multinational Clinical Trials, where the study was conducted.
This post was imported from a legacy archive. Please excuse any formatting inconsistencies.